Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Name: Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
License: Public Domain

ADC Therapeutics S.A.

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

lymphoma

relapsed or refractory diffuse large b-cell lymphoma (r/r dlbcl), expanded access, lymphoma, large b-cell, relapsed, refractory

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 866136
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.